文献速递基础与转化研究新药、器械与细胞基因治疗研发组学、生物样本库与精准医学

iPSC「培养皿临床试验」显示洛伐他汀改善LMNA心肌病内皮功能障碍与细胞交互

Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy.
PubMed 文献 · Sci Transl Med · 2020-01-01

研究聚焦LMNA相关扩张型心肌病(DCM)家系,用患者iPSC来源内皮细胞(iPSC-ECs)复现内皮功能障碍,并经ATAC-seq与RNA-seq及功能实验锁定KLF2;KLF2激动剂洛伐他汀可 rescue 内皮功能,患者反应性充血指数改善,且与iPSC-ECs共培养时改善iPSC-心肌细胞功能。

要点

  • LMNA相关DCM患者存在临床内皮功能障碍,iPSC-ECs显示血管生成与NO产生受损。
  • KLF2被鉴定为内皮功能障碍的潜在转录因子,洛伐他汀等KLF2激动剂可恢复内皮功能。
  • 洛伐他汀治疗患者反应性充血指数改善,提示他汀可能对cardiolaminopathy血管功能障碍有效。

核心结论

  • 内皮细胞与心肌细胞间交互受损可能参与LMNA相关DCM发病,他汀可能有效治疗cardiolaminopathy的血管功能障碍。

研究设计与样本

  • 研究一个LMNA移码变异所致DCM家系,由患者iPSC诱导生成内皮细胞并进行表型鉴定。
  • 采用基因组编辑同基因iPSC系、ATAC-seq与RNA-seq联合分析及功能获得/缺失研究。
  • 在患者来源iPSC-ECs与iPSC-CMs共培养体系中评估洛伐他汀对细胞功能的影响。

主要发现

  • LMNA相关DCM患者存在临床内皮功能障碍,其iPSC-ECs表现为血管生成受损与NO产生减少。
  • 基因组编辑校正LMNA的同基因iPSC-ECs恢复内皮功能,复现内皮疾病表型。
  • ATAC-seq与RNA-seq及功能缺失研究鉴定KLF2为内皮功能障碍的潜在转录因子。
  • KLF2激动剂洛伐他汀处理LMNA iPSC-ECs可 resc 内皮功能障碍。
  • 洛伐他汀治疗患者反应性充血指数升高,iPSC-CMs与iPSC-ECs及洛伐他汀共培养时CM功能改善。

临床怎么用

  • 对LMNA相关DCM患者可关注内皮功能障碍评估,反应性充血指数可作为临床内皮功能指标。
  • 洛伐他汀等KLF2激动剂可能作为cardiolaminopathy血管功能障碍的候选治疗,需进一步临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in LMNA, the gene that encodes lamin A and C, causes LMNA-related dilated cardiomyopathy (DCM) or cardiolaminopathy. LMNA is expressed in endothelial cells (ECs); however, little is known about the EC-specific phenotype of LMNA-related DCM. Here, we studied a family affected by DCM due to a frameshift variant in LMNA Human induced pluripotent stem cell (iPSC)-derived ECs were generated from patients with LMNA-related DCM and phenotypically characterized. Patients with LMNA-related DCM exhibited clinical endothelial dysfunction, and their iPSC-ECs showed decreased functionality as seen by impaired angiogenesis and nitric oxide (NO) production. Moreover, genome-edited isogenic iPSC lines recapitulated the EC disease phenotype in which LMNA-corrected iPSC-ECs showed restoration of EC function. Simultaneous profiling of chromatin accessibility and gene expression dynamics by combining assay for transposase-accessible chromatin using sequencing (ATAC-seq) and RNA sequencing (RNA-seq) as well as loss-of-function studies identified Krüppel-like factor 2 (KLF2) as a potential transcription factor responsible for the EC dysfunction. Gain-of-function studies showed that treatment of LMNA iPSC-ECs with KLF2 agonists, including lovastatin, rescued the EC dysfunction. Patients with LMNA-related DCM treated with lovastatin showed improvements in clinical endothelial dysfunction as indicated by increased reactive hyperemia index. Furthermore, iPSC-derived cardiomyocytes (iPSC-CMs) from patients exhibiting the DCM phenotype showed improvement in CM function when cocultured with iPSC-ECs and lovastatin. These results suggest that impaired cross-talk between ECs and CMs can contribute to the pathogenesis of LMNA-related DCM, and statin may be an effective therapy for vascular dysfunction in patients with cardiolaminopathy.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Sayed N, Liu C, Ameen M, et al. Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy. Sci Transl Med. 2020. PMID: 32727917. doi:10.1126/scitranslmed.aax9276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。